SciClone Pharmaceuticals Inc

SciClone Pharmaceuticals — Investor Presentation (January 2013)

22 slides from SciClone Pharmaceuticals's investor presentation, Jan 7, 2013

  1. Slide 1: Corporate Presentation January 2013

    Exhibit 99.2 Corporate Presentation January 2013 SciClone Pharmaceuticals A Top US Specialty Pharma Company Leveraging China Market Growth Opportunities

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “p

  3. Slide 3: SciClone Today: Earnings-Driven Specialty Pharma Company with Growing China Commercial Business

    SciClone Today: Earnings-Driven Specialty Pharma Company with Growing China Commercial Business Revenue & Profitability Established Multinational Growth Track Record Company Successful Products, Pipeline, Partnerships • Focus on high quality • Solid well-established business compliance and controls

  4. Slide 4: Positive Revenue and EPS Trends

    Positive Revenue and EPS Trends $180MM $1.00 $0.90 $160MM $0.80 $140MM $0.70 $120MM $0.60 $0.50 $100MM $0.40 $80MM $0.30 $60MM $0.20 $0.10 $40MM $0.00 $20MM ($0.10) $0MM ($0.20) 2008 2009 2010 2011 2012 2013 Guidance Guidance Revenue Non-GAAP Basic EPS 4

  5. Slide 5: Consistently Growing Profits and Cash Flow

    Consistently Growing Profits and Cash Flow FY 2013 FY2012 FY 2011 FY 2010 FY 2009 Guidance Guidance Revenue $150-$155MM $152-$157MM $134MM $85MM $72MM EPS* $0.66-$0.72** $0.62-$0.68** $0.62** $0.44 $0.26 Cash & >$105MM*** $87MM $67MM $57MM $32MM Investments *Basic **Non-GAAP ***Excludes effect of sh

  6. Slide 6: Creating Shareholder Value through Share Repurchases and Cash Balances

    Creating Shareholder Value through Share Repurchases and Cash Balances 2013 Estimate FY2012 FY 2011 Shares 2.5MM 4.7MM 0.8MM Repurchased Cash used in $12.4MM $24.8MM $3.5MM Repurchases 6

  7. Slide 7: Partnering Strategy to Drive Top Line and Profitability

    Partnering Strategy to Drive Top Line and Profitability • Partner of choice positioning, Xatral Urology leveraging commercial and regulatory Depakine CNS expertise Stilnox CNS Tritace Cardiovascular • Renegotiating promotion agreements to achieve more favorable terms and Holoxan Oncology increased p

  8. Slide 8: Strategy for Continued Sales and Profit Growth

    Strategy for Continued Sales and Profit Growth Build momentum for high-margin marketed portfolio in China Drive ZADAXIN growth Build on the solid base for established products: Depakine ® Develop future market leaders: Aggrastat, Stillnox Increase profitability Structure licensing and promotion agre

  9. Slide 9: Product Portfolio: Current and Future Market Leaders

    Product Portfolio: Current and Future Market Leaders 9

  10. Slide 10: Product and Development Portfolios Span Large, Growing Commercial Markets

    Product and Development Portfolios Span Large, Growing Commercial Markets Marketed Products Immunostimulant for HBV, HCV, cancer, vaccine adjuvant; proprietary product Broad-spectrum anti-convulsant for epilepsy; bipolar disorder; exclusively promoted for Sanofi Non-benzodiazepine hypnotic for sleep

  11. Slide 11: ZADAXIN: Immune stimulator for severe hepatitis and oncology

    • Immune stimulator for treatment in severe hepatitis and oncology • Acts through TLR9 pathway • Effective in immune system compromised patients • Clinical demonstration of quality-of-life benefits • Indications: HBV, HCV, certain cancers; vaccine adjuvant • Proprietary to SciClone: registered in Ch

  12. Slide 12: ZADAXIN in China – Commercial Growth Opportunity

    ZADAXIN ( ) in China – Commercial Growth Opportunity • Thymosins(ZADAXIN category) top 5 category product in China • Key advantage: high-quality Western manufacturing • Highly differentiated: no imported competitors • Sales reaching more than $100M • 40%+ of RMB value share, 13% of volume share desp

  13. Slide 13: Market Advantages Potentially Driving Increased Demand for ZADAXIN

    Market Advantages Potentially Driving Increased Demand for ZADAXIN • Recent price reductions likely to increase volume and market penetration • Increased affordability for broader range of hospitals and patients • Strengthen provincial tendering strategies • Independent listing from generics support

  14. Slide 14: Depakine – CNS Market Leader

    Depakine ® – CNS Market Leader Description • Broad spectrum treatment for epileptic attacks and syndromes; bipolar disorder • Licensed from Sanofi-Aventis; exclusive China promotion rights • Year of China registration: 2008 nd Commercial • SciClone’s 2 largest product: Opportunity sales grew ~28% CA

  15. Slide 15: Aggrastat – Future Cardiovascular Market Leader

    Aggrastat ®–Future Cardiovascular Market Leader Description • Intervention cardiology product • Fast acting, reversible IIb/IIIa inhibitor that disaggregates platelet thrombi and improves myocardial perfusion • Improves results of those at high risk of MI 3-4 days post- acute angina (including patie

  16. Slide 16: Stillnox – Market Leader in Sleep Disorders

    Stillnox®–Market Leader in Sleep Disorders Description • Non-benzodiazepine hypnotic • Exclusively promoted for Sanofi-Aventis • Year of China registration: 2008 Commercial High growth potential in tier 1 Opportunity cities and large institutions; strong efficacy, favorable side-effect profile Marke

  17. Slide 17: Path to Continued Earnings Growth and Value Creation

    Path to Continued Earnings Growth and Value Creation 17

  18. Slide 18: China Pharma Market is Major Growth Opportunity for SciClone

    China Pharma Market is Major Growth Opportunity for SciClone • Predicted to grow at least 15-20% compared to essentially flat US, EU markets • Increased consumer demand • Broader access to health care services • Current and future growth largely located in second-tier and rural areas • Growing deman

  19. Slide 19: Established Multinational Company Ranking in Top Tier in China Market

    Established Multinational Company Ranking in Top Tier in China Market • US corporate headquarters: China operations report into US • Experienced international management teams in US and China • Attracting leading local management talent in China • Strong commercial, regulatory, reimbursement capabil

  20. Slide 20: Strategy to Leverage China Pharma Market Growth Opportunities

    Strategy to Leverage China Pharma Market Growth Opportunties • Build on our well established commercial, regulatory management strengths • Take advantage of growth trends in the China pharmaceutical market • Deploying experienced sales and marketing teams to key geographies • Further capitalize on o

  21. Slide 21: SciClone: Unique Investment Opportunity to Participate in Growing China Pharma Market

    SciClone: Unique Investment Opportunity to Participate in Growing China Pharma Market Strong Balance Sheet A Partner of Choice for Promising In-Licensing Late-Stage Broad Pipeline Portfolio of Profitable Marketed Products with Significant Growth US-based, Potential China-focused 21

  22. Slide 22: SciClone Pharmaceuticals

    @SciCrone’ PHARMACEUTICALS

SciClone Pharmaceuticals — Investor Presentation (January 2013) on 6ix